Malignant Melanoma Medical Services in China

Malignant melanoma is a highly aggressive form of cutaneous malignancy arising from melanocytes, with the potential for early hematogenous and lymphatic metastasis. It accounts for the majority of skin cancer–related mortality despite representing only ~5% of all skin cancers. Risk factors include UV radiation exposure, fair skin phenotype, numerous atypical nevi, and family history. Clinical subtypes include superficial spreading, nodular, lentigo maligna, and acral lentiginous melanoma—with the latter being disproportionately prevalent among Asian populations. Diagnosis relies on dermoscopic evaluation, excisional biopsy, histopathologic assessment (including Breslow thickness, ulceration status, mitotic rate), and staging via sentinel lymph node biopsy and imaging (e.g., PET-CT, MRI). Treatment is stage-dependent: wide local excision for localized disease; adjuvant immunotherapy (e.g., anti-PD-1 agents like pembrolizumab or nivolumab) or targeted therapy (BRAF/MEK inhibitors for BRAF V600-mutated cases) for high-risk or advanced disease; and multimodal approaches—including surgery, radiotherapy, and systemic therapies—for metastatic involvement.

China offers distinct advantages in melanoma management: leading dermatologic oncology centers—such as Peking University First Hospital and Fudan University Shanghai Cancer Center—combine deep expertise in acral and mucosal melanoma subtypes with access to FDA- and NMPA-approved immunotherapies and next-generation sequencing platforms. Robust clinical trial participation and real-world evidence demonstrate comparable progression-free survival to Western benchmarks, particularly in adjuvant and unresectable settings. Costs for comprehensive care—including genomic profiling, checkpoint inhibitors, and surgical resection—are typically 40–60% lower than in the US or EU, without compromising protocol adherence or multidisciplinary oversight. As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying physician credentials, coordinating appointments at JCI-accredited hospitals, providing itemized, transparent pricing in advance, arranging interpreters and post-treatment follow-up, and offering end-to-end support—from visa assistance to accommodation—ensuring continuity of care and informed decision-making.

Medical Travel to China Guide: Malignant Melanoma (Dermatology)

Travelers seeking treatment for malignant melanoma in China must obtain a Medical Visa (Q2 or X1, depending on duration). A confirmed hospital appointment letter and invitation from a licensed Chinese medical institution are required. Passport validity must exceed six months, and applicants should apply through the Chinese embassy or consulate in their home country.

Medical insurance is not accepted by most Chinese hospitals; patients pay directly. We provide transparent, itemized pricing upfront—including diagnostics, surgery, immunotherapy, and pathology—and assist with secure international bank transfers, credit card payments (Visa/Mastercard), or cash (RMB/USD/EUR). Our team negotiates fair rates and ensures no hidden fees.

We arrange comfortable, hospital-proximity accommodations (hotels or serviced apartments) and support companion visas, airport transfers, and local logistics.

Post-treatment, our agency coordinates follow-up care: remote consultations with treating oncologists/dermatologists, digital pathology review, medication shipping, and seamless handover to your home physician—with bilingual medical summaries and treatment records provided within 48 hours of discharge.